NCT04459676Unknown2 期
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 10
- 主要终点
- Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28
研究概览
简要总结
To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is a male or nonpregnant female 18 years of age or older.
- •Patient has a positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for SARS-CoV-2 in a respiratory tract sample during the current hospital admission.
- •Patient has pneumonia confirmed by chest imaging.
- •Patient has moderate to severe disease based on the WHO disease severity scale assessment at the time of randomization defined as:
- •Score 4, only those with FiO2 > 40%
- •Score 5 (Non-invasive ventilation or high-flow oxygen)
- •Patient has ability to provide informed consent signed by study patient or legally acceptable representative.
- •Patient has willingness and ability to comply with study-related procedures/assessments
排除标准
- •Has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. Patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed > 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment.
- •Patient is pregnant or breast-feeding.
- •Patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening.
- •Patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study.
- •Patient with alanine aminotransferase (ALT) or aspartate transaminase (AST) > 3x upper limit of normal (ULN) and/or total bilirubin > 2xULN at baseline
- •Patient requires treatment with the cytochrome P450 1A2 (CYP1A2) inhibitors, ciprofloxacin (Cipro®) and/or fluvoxamine (Luvox®)
- •Patients participating in any other clinical trial with an investigational drug product or procedure
- •Recipients of solid organ and/or hematopoietic cell transplantation
- •Patient is known to have End Stage Renal Disease (ESRD) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization.
- •Note: Patients who initiated RRT due to Acute Kidney Injury during their current hospitalization will be eligible for the study
研究组 & 干预措施
ANG-3777 + SOC
Active Comparator
ANG-3777 Administered IV for 30 min and SOC
Repeat within 24 hours after previous dosing for a total of 4 days
干预措施: Standard of Care (SOC) + ANG-3777 (Drug)
Standard of Care + Placebo
Placebo Comparator
Standard of Care + Placebo
干预措施: Standard Of Care (SOC) + Placebo (Drug)
结局指标
主要结局
Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28
时间窗: From the time of randomization until (Day 1) until death or until Day28, whichever comes first
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
Unknown
2 期
Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary BypassAcute Kidney InjuryNCT02771509Angion Biomedica Corp275
Unknown
3 期
Reduce the Severity of DGF in Recipients of a Deceased Donor KidneyDelayed Graft FunctionNCT02474667Angion Biomedica Corp253
已完成
3 期
Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore ThroatSore ThroatNCT03095508Sandoz229
Unknown
1 期
Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc IntervalHealthy VolunteerNCT04898907Angion Biomedica Corp48
Unknown
2 期
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney DiseaseGlomerular DiseaseProteinuriaNCT04939116Angion Biomedica Corp100